A new, highly transmissible COVID subvariant, NB.1.8.1, has been detected in California, raising concerns of a potential summer surge. Simultaneously, recent federal actions have rescinded recommendations for COVID-19 vaccination in pregnant women and healthy children under 65, potentially limiting vaccine access and increasing costs. This decision, opposed by many experts, could lead to reduced vaccination rates and increased vulnerability to the new subvariant. While NB.1.8.1 doesn’t appear to cause more severe illness, its higher transmissibility is a significant concern, particularly given the potential for reduced vaccine uptake. Experts warn that the changes could place a larger financial burden on individuals seeking vaccination.
Read More
A new COVID-19 variant, NB.1.8.1, is spreading in the U.S., though its presence is underreported on federal dashboards due to low case numbers. While currently less prevalent than LP.8.1, NB.1.8.1 has been detected in several states and is linked to increased hospitalizations in Asia. The World Health Organization classifies the global public health risk as low, but experts note its increased transmissibility compared to previous variants. Despite this, current COVID-19 vaccines are expected to remain effective against NB.1.8.1.
Read More
The FDA announced a significant policy shift, ending routine annual COVID-19 vaccinations for healthy younger adults and children. Future COVID-19 vaccine approvals will require extensive studies, prioritizing high-risk individuals (adults 65+ and those with underlying health conditions). This new framework, published in the *New England Journal of Medicine*, marks a departure from the previous “one-size-fits-all” approach and raises concerns about vaccine accessibility and insurability. The decision follows criticism of the U.S.’s aggressive booster recommendations compared to other nations.
Read More
John Q. Hosedrinker